LuciVemu (Vemurafenib) 240mg Tablets | Laos Generic | GLT

Generic Information: LuciVemu (Vemurafenib) — Lucius Pharmaceuticals Laos Generic

LuciVemu is a Laos-manufactured generic of vemurafenib, produced by Lucius Pharmaceuticals (Lao) Co., Ltd., a pharmaceutical company based in Vientiane, Laos. This page covers the 240 mg film-coated tablet supplied in a 56-tablet box. LuciVemu delivers the same BRAF V600E-targeting mechanism as the originator Zelboraf but at a far more accessible price, making precision oncology reachable for melanoma patients who face prohibitive costs for the branded product. Each tablet contains 240 mg of vemurafenib, and the product is manufactured under a registration that reflects the growing role of Laos-based manufacturers in providing affordable targeted therapies to patients across Southeast Asia and beyond.

What Is LuciVemu (Vemurafenib) Used For?

LuciVemu is used for the treatment of unresectable or metastatic melanoma in patients whose tumors carry the BRAF V600E mutation, as well as for Erdheim-Chester Disease with the BRAF V600 mutation. These are the same two indications as the originator, giving physicians and patients a lower-cost route to the same class of targeted therapy. For patients who need a BRAF inhibitor but cannot afford the branded medicine, LuciVemu represents a practical, affordable alternative that preserves the mechanism of action that has transformed outcomes in BRAF-mutant melanoma.

How Does LuciVemu (Vemurafenib) Work?

LuciVemu contains vemurafenib, a selective inhibitor of the mutant BRAF V600E kinase. In BRAF-mutant tumors, the mutated kinase is locked into a constantly active state that drives relentless cell division through the MAPK signaling pathway. By binding and inhibiting this overactive enzyme, vemurafenib switches off the oncogenic signal, slowing tumor growth and, in many cases, shrinking established lesions. Because the drug specifically targets the mutant protein, a confirmatory BRAF V600E test is required before treatment, and it must not be used in patients with wild-type BRAF melanoma.

Indications

LuciVemu is indicated for: (1) the treatment of patients with unresectable or metastatic melanoma with the BRAF V600E mutation, as detected by an approved test; and (2) the treatment of patients with Erdheim-Chester Disease with the BRAF V600 mutation. It is not indicated for wild-type BRAF melanoma.

Dosage

The recommended dose is 960 mg (four 240 mg tablets) taken orally twice daily, about 12 hours apart, with or without food. Treatment should begin only after confirming the BRAF V600E mutation in tumor tissue. The tablets are swallowed whole. Therapy continues until disease progression or unacceptable toxicity, with dose modification managed according to the appearance of adverse reactions and any QT-interval changes.

Side Effects

As with all BRAF inhibitors, the most common adverse reactions include arthralgia, rash, alopecia, fatigue, photosensitivity, nausea, pruritus, and skin papillomas. Patients should be monitored for new skin lesions, including cutaneous squamous cell carcinoma, and for signs of QT prolongation, liver injury, and eye inflammation. Dermatologic evaluation is recommended before treatment and periodically during therapy, and patients should avoid excessive sun exposure and use sun protection.

Storage

Store LuciVemu tablets in a dry place at 20°C to 25°C, protected from moisture. Keep out of the reach of children and do not use beyond the expiry date.

Why Choose the GLT?

LuciVemu offers the same BRAF-targeting therapy as the originator at a fraction of the cost, which matters enormously for patients who must take the medicine twice daily over an extended period. The originator Zelboraf carries a monthly cost in Western markets that runs into five figures, placing it out of reach for many families; LuciVemu from Lucius Pharmaceuticals closes that gap by delivering an affordable, Laos-manufactured alternative. As a Hong Kong-licensed supplier, GLT provides a dependable, verified channel for this generic, with batch documentation and transparent pricing that helps patients access life-extending treatment without financial ruin.

How to Order LuciVemu (Vemurafenib)

To order LuciVemu, contact our team on WhatsApp at +86 15234153837 or by email at [email protected]. Please share the required quantity, your destination country, and any documentation needs so we can confirm current availability and delivery terms.

FAQ

Is LuciVemu a generic of Zelboraf? Yes. LuciVemu is a Laos-manufactured generic of vemurafenib, the same active ingredient in the originator Zelboraf.

Who makes LuciVemu? LuciVemu is produced by Lucius Pharmaceuticals (Lao) Co., Ltd., based in Vientiane, Laos.

What is LuciVemu used for? It treats unresectable or metastatic melanoma with the BRAF V600E mutation and Erdheim-Chester Disease with the BRAF V600 mutation.

Does LuciVemu require BRAF testing? Yes. A confirmatory BRAF V600E test is required before treatment, and the drug must not be used in wild-type BRAF melanoma.